Joint Formulary & PAD

Alimemazine tartrate - Sleep disorders in children and adolescents

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Associated Icons :
BNF SPC
NFD1
Un
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Alimemazine tartrate
Indication :
Sleep disorders in children and adolescents
Group Name :
Keywords :
ADHD, sedating antihistamines, trimeprazine
Brand Names Include :
Vallergan, Itzenal
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Alimemazine tartrate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Sleep disorders in children and adolescents.

Committee Recommendations (1)

The PCN does not recommend alimemazine (trimeprazine) for the unlicensed treatment of sleep disorders in children and adolescents. Alimemazine (trimeprazine) will be considered BLACK on the traffic light system for new patients Patients whose treatment with alimemazine was initiated by the NHS before this recommendation was made must be reviewed by their NHS consultant within 12 months but, should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.

 

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.